How many LIXT restricted share units does Felix Lourdes hold after this grant?

Following the grant, Felix Lourdes holds 55,000 restricted share units in total. This amount includes the 30,000 newly awarded RSUs plus 25,000 RSUs that had already vested, consolidating his equity-based compensation position as disclosed in the Form 4 filing.

Did Felix Lourdes pay cash to acquire the 30,000 LIXT restricted share units?

No cash was paid for the 30,000 RSUs, which were granted at a reported price of $0.0000 per unit. This indicates they were issued as equity compensation under the 2020 Stock Incentive Plan rather than purchased in an open-market transaction.

LIXTE director granted 30,000 RSUs in equity award

Felix Lourdes reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Felix Lourdes reported acquisition or exercise transactions in this Form 4 filing.

LIXTE Biotechnology Holdings director Felix Lourdes received a grant of 30,000 restricted share units (RSUs) under the company’s 2020 Stock Incentive Plan. The RSUs represent the right to receive an equal number of common shares upon vesting, and the performance conditions for these 30,000 RSUs have been satisfied.

After this award, Lourdes holds a total of 55,000 RSUs, including 25,000 RSUs that have already vested. The grant was a compensation award with no cash paid per share.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Felix Lourdes

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 55,000 shares (Direct)

Footnotes (2)

F1. The reported transaction involved the Reporting Person's receipt of 30,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.
F2. The total reported in Column 5 includes (i) the 30,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

Key Figures

RSUs granted: 30,000 RSUs Total RSUs after grant: 55,000 RSUs Previously vested RSUs: 25,000 RSUs +1 more

4 metrics

RSUs granted 30,000 RSUs Restricted share units awarded to Felix Lourdes as of 2026-07-01

Total RSUs after grant 55,000 RSUs Aggregate RSUs held by Felix Lourdes following the transaction

Previously vested RSUs 25,000 RSUs RSUs included in the total that had already vested

Grant price per RSU $0.0000 per unit Indicates equity compensation with no cash paid

Key Terms

restricted share units ("RSUs"), 2020 Stock Incentive Plan, performance conditions

3 terms

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."

performance conditions financial

"The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LIXT director Felix Lourdes report on this Form 4?

Felix Lourdes reported receiving 30,000 restricted share units as a compensation award. These RSUs were granted under Lixte Biotechnology Holdings’ 2020 Stock Incentive Plan and convert into common shares upon vesting, reflecting an equity-based incentive rather than an open-market share purchase.

Were the 30,000 LIXT RSUs granted to Felix Lourdes subject to performance conditions?

Yes, the 30,000 RSUs were tied to performance conditions specified in Lourdes’ RSU agreement. The Form 4 states that these performance conditions have been satisfied, meaning the RSUs have vested and now represent a right to receive Lixte common stock, subject to continued service.

What plan governed the 30,000 LIXT RSU grant to Felix Lourdes?

The 30,000 restricted share units were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. The RSUs are also subject to the specific terms of Lourdes’ RSU agreement, which outlines performance conditions and the service requirements for vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/02/2026 - 04:08 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Felix Lourdes

(Last)

(First)

(Middle)

433 PLAZA REAL SUITE 275

(Street)

BOCA RATON

FLORIDA

33432

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		A		30,000⁽¹⁾	A	$0	55,000⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of 30,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

2. The total reported in Column 5 includes (i) the 30,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

	/s/ Lourdes Felix	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR